GlassScriptPhysician profile
Mee Yung Knapp
NPI 1548402233
$2,384.12
in general payments reported to CMS, 2019-2025
20 companies · $341 in 2025
The $341 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $321 · 2021: $540 · 2022: $338 · 2023: $274 · 2024: $331 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $455.29 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $449.00 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $336.12 | 2019-2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $298.70 | 2024-2025 | |
| Glaxosmithkline, LLC. | $136.01 | 2019-2021 | |
| Adlon Therapeutics L.P. | $111.11 | 2020-2021 | |
| Neos Therapeutics, LP | $97.19 | 2019-2024 | Cotempla Xr-Odt |
| Sobi, INC | $94.13 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $66.02 | 2021-2024 | Qelbree, Qelbree |
| Cranial Technologies, INC | $64.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.86 | 2020-2021 | |
| Sanofi Pasteur INC. | $48.97 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $44.40 | 2021-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $36.95 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $20.34 | 2024 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.49 | 2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $17.25 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $14.37 | 2025 | Jornay Pm |
| Alk-Abello, INC | $14.07 | 2025 | Neffy |
| Seqirus USA INC | $12.75 | 2023 | Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mee Yung Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.